Berger JS, et al. JAMA 2009;301:1909-19.

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Analyses of Covariance Comparing k means adjusting for 1 or more other variables (covariates) Ho: u 1 = u 2 = u 3 (Adjusting for X) Combines ANOVA and.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

The Relative Safety and Efficacy of Clopidogrel in Women and Men: A Sex-Specific Meta-Analysis Jeffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon,

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Flow diagram of the systematic literature search indicating the inclusion and exclusion process of studies Liakopoulos OJ, et al. Eur Heart J 2008;29:

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Influenza Vaccination and Cardiovascular.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Discontinuation of medication after nonfatal event: MI

The SPRINT Research Group

Structure of Cis and Trans Fatty Acids

Copyright © 2012 American Medical Association. All rights reserved.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

Copyright © 2011 American Medical Association. All rights reserved.

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Copyright © 2012 American Medical Association. All rights reserved.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational.

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis S Hajibandeh, S Hajibandeh,

Introduction The American Journal of Medicine

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Relative risk of major events with atenolol vs placebo

Use of Targeted Temperature Management After Out-of-hospital Cardiac Arrest: A Meta- Analysis of Randomized Controlled Trials Ahmed Mahmoud, MD, Islam.

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery George A. Antoniou, MD, PhD, MSc, FEBVS, Shahin.

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD

Flow Diagram of the Trial Selection Process

Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal.

Women’s Health Study: Baseline Characteristics Part 1

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Study Flow Diagram Thompson A, et al. JAMA 2008;299:

Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: Duminda N Wijeysundera, MD, Jennifer S Naik, MD, W Scott Beattie, MD,

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.

Zachary L. Steinberg et al. JACC 2017;69:

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Christian Madelaire et al. JCHF 2018;6:

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

M. Hassan Murad, MD, MPH, David N. Flynn, BS, Mohamed B

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Gianluigi Savarese et al. JCHF 2016;4:

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Presentation transcript:

Berger JS, et al. JAMA 2009;301:1909-19

Flow Diagram of the Literature Search and Trial Selection Process Berger JS, et al. JAMA 2009;301:1909-19

Design of Trials Included in the Meta-analysis - Part I Berger JS, et al. JAMA 2009;301:1909-19

Design of Trials Included in the Meta-analysis - Part II Berger JS, et al. JAMA 2009;301:1909-19

Effect of Any Aspirin on the Prevention of Composite Cardiovascular End Points Berger JS, et al. JAMA 2009;301:1909-19

Effect of Any Aspirin on the Prevention of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Cardiovascular Death Zero weight denotes a study in which there were no occurrences of the indicated event. A blank row denotes a study in which the indicated event was not measured. a - Pooled relative risks (RRs) are from a random-effects model. CI indicates confidence interval. Zero weight denotes a study in which there were no occurrences of the indicated event. A blank row denotes a study in which the indicated event was not measured. aPooled relative risks (RRs) are from a random-effects model. CI indicates confidence interval. Berger JS, et al. JAMA 2009;301:1909-19

Effect of Any Aspirin on the Prevention of Any Death and Major Bleed Zero weight denotes a study in which there were no occurrences of the indicated event. A blank row denotes a study in which the indicated event was not measured. aPooled relative risks (RRs) are from a random-effects model. CI indicates confidence interval. Berger JS, et al. JAMA 2009;301:1909-19

Effect of Aspirin Monotherapy on the Prevention of Adverse Outcomes Major cardiovascular events defined as the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Zero weight denotes a study in which there were no occurrences of the indicated event. A blank row denotes a study in which the indicated event was not measured. a - Pooled relative risks (RRs) are from a random-effects model. CI indicates confidence interval. Major cardiovascular events defined as the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Zero weight denotes a study in which there were no occurrences of the indicated event. A blank row denotes a study in which the indicated event was not measured. aPooled relative risks (RRs) are from a random-effects model. CI indicates confidence interval. Berger JS, et al. JAMA 2009;301:1909-19